Most importantly, the inhibition of tumor growth in an orthotopic xenograft mouse model of PDAC and TNBC via lipid-based nanoparticle delivery of miR-873 suggests that strategies targeting the miR-873/KRAS axis may provide broad antitumor effects through the inhibition of multiple oncogenic pathways. This evidence concerns the gene KRAS and neoplasm.